Anakinra

Anakinra
Clinical data
Trade namesKineret
AHFS/Drugs.comMonograph
MedlinePlusa602001
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability95%
Metabolismpredominantly kidney
Elimination half-life4-6 hrs
Identifiers
  • Recombinant human Interleukin-1 receptor antagonist protein; syn. N2-l-methionyl-interleukin 1 receptor antagonist (human isoform x reduced)
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC759H1186N208O232S10
Molar mass17257.66 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease.[3] It is a slightly modified recombinant version of the human interleukin 1 receptor antagonist protein.[3] It is marketed by Swedish Orphan Biovitrum.[1] Anakinra is administered by subcutaneous injection.[2]

  1. ^ a b "Kineret 100 mg solution for injection in a pre-filled syringe - Summary of Product Characteristics (SmPC)". UK Electronic Medicines Compendium. Retrieved 2 March 2022.
  2. ^ a b Cite error: The named reference Kineret FDA label was invoked but never defined (see the help page).
  3. ^ a b c "Kineret EPAR". European Medicines Agency. 17 September 2018. Retrieved 20 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.